Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MANNKIND CORP (MNKD)

MannKind Q3 revenue up 24% to $101.9 million, but swings to $23.2 million net loss

Mixed Impact 3 of 5 earnings Written later

MannKind reported third quarter 2026 total revenues of $101.9 million, up 24% from a year earlier, mainly due to Furoscix, acquired from scPharma in October 2025. The company posted a net loss of $23.2 million, or $0.07 per share, compared with net income of $8.0 million, or $0.03 per share, in the prior-year quarter, as selling, general and administrative expenses rose to $61.4 million. For shareholders, revenue growth came with higher costs and a loss, and the company reported $96.6 million in cash, cash equivalents and investments as of September 30, 2026.

Key points

  • Total revenues were $101.9 million, up from $82.1 million in Q3 2025; Furoscix contributed $22.4 million.
  • Net loss was $23.2 million ($0.07 per share), compared with net income of $8.0 million ($0.03 per share) a year earlier.
  • Selling, general and administrative expenses were $61.4 million, up 111% from $29.1 million; commercial cost of goods sold was $11.2 million vs. $4.5 million.
  • Furoscix ReadyFlow shipments began in mid-September, and about 75% of weekly Furoscix shipments had transitioned to ReadyFlow by late October.

The filing

CompanyMANNKIND CORP (MNKD)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:03 PM ET
Accession number0001193125-26-449743

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.